ZYNEX INC (ZYXI) - Dilution Analysis

8-K filing: The company issued 1,000 shares of common stock to Altivera Medical Holdings LLC, the Plan Sponsor, in connection with its emergence from Chapter 11.

RW filing: This is an RW filing for Zynex, Inc. requesting the withdrawal of a Registration Statement on Form S-3 (File No. 333-286780) due to the company's Chapter 11 bankruptcy filing.

10-Q filing | 30.3M shares outstanding

10-Q filing | 31.6M shares outstanding

S-3 filing: Zynex Inc. files an S-3 to offer common stock, preferred stock, warrants, rights, or a combination of these securities, or units, for an aggregate initial offering price of up to $100,000,000.

8-K filing: On March 13, 2025, Zynex, Inc. purchased 1,700,000 shares of the Company's common stock from Thomas Sandgaard at a price of $2.905 per share.

10-K filing | 31.9M shares outstanding

10-Q filing | 31.8M shares outstanding

10-Q filing | 31.8M shares outstanding

10-Q filing | 32.3M shares outstanding

10-K filing | 32.2M shares outstanding

10-Q filing | 35.5M shares outstanding

8-K filing: Zynex, Inc. amended its Stock Purchase Agreement with Kestrel Labs, Inc. to release the Escrow Fund in its entirety to the Selling Shareholders.

10-Q filing | 36.4M shares outstanding

8-K filing: Zynex, Inc. authorized a share repurchase plan for up to $10.0 million of the Company's common stock and purchased 300,000 shares from Thomas Sandgaard at $8.62 per share.

8-K filing: Zynex, Inc. purchased 300,000 shares of its common stock from Thomas Sandgaard, Chairman, President and Chief Executive Officer, at a price of $9.61 per share. ($2.88M proceeds)

8-K filing: Zynex, Inc. priced a private offering of $52,500,000 in aggregate principal amount of its 5.00% Convertible Senior Notes due 2026, with the initial purchaser exercising their option to purchase additional Notes in full, bringing the total aggregate principal amount of the Notes to $60,000,000.

10-Q filing | 36.7M shares outstanding

10-K filing | 38.5M shares outstanding

10-Q filing | 38.0M shares outstanding

10-Q filing | 38.9M shares outstanding

10-Q filing | 39.8M shares outstanding

10-K filing | 39.2M shares outstanding

8-K filing: Zynex, Inc. entered into a Stock Purchase Agreement to acquire Kestrel Labs, Inc. by exchanging $16.0 million cash and 1,334,350 shares of Zynex's common stock to Kestrel's shareholders.

10-Q filing | 34.8M shares outstanding

10-Q filing | 34.8M shares outstanding

10-Q filing | 34.8M shares outstanding

10-K filing | 34.9M shares outstanding

8-K filing: Thomas Sandgaard, CEO and Chairman of Zynex, Inc., adopted a written sales plan on December 3, 2020, to sell up to 400,000 shares of the Company's common stock, starting December 15, 2020, and ending May 1, 2021, at minimum prices ranging from $26.10 to $33.10.

10-Q filing | 34.5M shares outstanding

10-Q filing | 34.5M shares outstanding

8-K filing: Zynex, Inc. entered into an Underwriting Agreement for a public offering of 1,250,000 primary shares of common stock at $22.00 per share, with net proceeds to the Company of approximately $25.2 million. ($27.5M proceeds)

8-K filing: Thomas Sandgaard, CEO of Zynex, Inc., adopted a Rule 10b5-1 sales plan to sell up to 500,000 shares of the company's common stock between June 1, 2020, and May 1, 2021, at prices ranging from $30.10 to $50.10.

10-Q filing | 33.7M shares outstanding

10-K filing | 32.5M shares outstanding